

Figure S1. Changes in body weight and weekly body weight gain measured in control and 1 mg/kg/day risperidone-treated SD-fed mice over the 56-day period.




Figure S2. Changes in serum soluble leptin receptor levels measured in control and 1 mg/kg/day risperidone-treated obese mice over the 56-day period. ** $P < 0.01$.




Figure S3. Changes in serum serotonin levels measured in control and 1 mg/kg/day risperidone-treated obese mice over the 56-day period. *** $P < 0.001$.




Figure S4. Changes in serum FGF-21 levels measured in control and 1 mg/kg/day risperidone-treated obese mice over a 56-day period. *** $P < 0.001$.




Figure S5. Changes in (a) islet morphology (H&E stain and immunohistochemical stain; 200× magnification) and (b) β -cell percentage measured in control and 1 mg/kg/day risperidone-treated obese mice over a 56-day period. *** $P < 0.001$.




Figure S6. Changes in pancreatic (a) catalase, (b) GPx, and (c) SOD activities in the 1 mg/kg/day risperidone treatment and control groups over the 56-day treatment period. *** $P < 0.001$.




Figure S7. Changes in the serum levels of (a) TNF- α and (b) IL-1 β measured in control and 1 mg/kg/day risperidone-treated obese mice over a 56-day period. ** $P < 0.01$.




Figure S8. Changes in (a) immunohistochemical stain (200 \times magnification) and (b) kidney levels of IL-1 β measured in control and 1 mg/kg/day risperidone-treated obese mice over a 56-day period. *** $P < 0.001$.